A bill that would require pharmaceutical firms to provide free insulin on both an emergency and ongoing basis to income-eligible Minnesota residents has been passed by a state Senate committee. Under the legislation, eligible patients would be required to pay a $75 copay to the pharmacy for a 30-day insulin supply.
Eisai said it will comply with an FDA request to pull its weight-loss drug Belviq, or lorcaserin, and its extended-release formulation, Belviq XR, from the US market. The FDA issued the request after a postmarketing study found treatment was associated with increased incidence of lung, colorectal and pancreatic cancers.
A survey in the Journal of the American Medical Association found that of 371 hospices, 31% reported at least one case in which drugs were taken from a patient in the past 90 days, most often by relatives or caregivers. Lead researcher John Cagle said the issue may be even more significant than the numbers show but expressed worry that any response to concerns about drug diversions could compromise patient access to needed medications.
Amryt Pharma's lipodystrophy drug Myalept is the most expensive prescription drug in the US this year with a monthly list price of $71,306. Horizon Therapeutics' Ravicti was the second most expensive at $55,341 per month, and EMD Serono's Mavenclad, which has a monthly list price of $53,730, was third on the list.
Amgen has filed a patent infringement suit against Pfizer and its Hospira unit based on their proposed biosimilar of Amgen's Neulasta, or pegfilgrastim, which is used for reducing the rate of infection in patients undergoing myelosuppressive chemotherapy. Amgen alleges Hospira is infringing a patent related to methods of protein purification.
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 270 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.
Contact PCMA Charles Cote
Vice President, Strategic Communications